|Articles|November 20, 2007

Matthew Kurtz

Matthew Kurtz, Regional Sales Manager

T: (212) 951-6751
F: (212) 951-6604
mkurtz@advanstar.com

Covers New York, New Jersey, and international outside Canada

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Merck to Acquire Cidara for $9.2 Billion

ByMike Hollan

November 14th 2025

Invictus Pharmacy Becomes First US Pharmacy to Accept Cryptocurrency for Prescriptions

ByNicholas Saraceno, Editor

November 14th 2025

Image Credit: Adobe Stock Images/Grandbrothers

Komzifti Gains FDA Approval, Giving Kura Oncology and Kyowa Kirin a Key Strategic Win in NPM1-Mutated AML

ByDavy James

November 14th 2025

Pharmaceutical Executive Daily: WeightWatchers Planning to Offer Wegovy Following Approval

ByNicholas Jacobus

November 14th 2025

How Are Executives Adapting Their Growth Strategies to the Current Environment?

ByMike Hollan,Craig Ackerman

November 14th 2025

Matthew Kurtz

Newsletter

Related Content

Merck to Acquire Cidara for $9.2 Billion

Invictus Pharmacy Becomes First US Pharmacy to Accept Cryptocurrency for Prescriptions

Komzifti Gains FDA Approval, Giving Kura Oncology and Kyowa Kirin a Key Strategic Win in NPM1-Mutated AML

Pharmaceutical Executive Daily: WeightWatchers Planning to Offer Wegovy Following Approval

How Are Executives Adapting Their Growth Strategies to the Current Environment?

Trending on PharmExec

The Influence of Targeting CCR5 Receptors

Merck to Acquire Cidara for $9.2 Billion

Komzifti Gains FDA Approval, Giving Kura Oncology and Kyowa Kirin a Key Strategic Win in NPM1-Mutated AML

DEI Changes in Pharma: A Look Back at 2025 & Predictions for 2026

Pharmaceutical Executive Daily: WeightWatchers Planning to Offer Wegovy Following Approval